Regeneron Pharmaceuticals (REGN) Net Equity Issued and Repurchased (2009 - 2026)

Regeneron Pharmaceuticals' Net Equity Issued and Repurchased history runs 18 years deep, the most recent figure standing at $163.1 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased rose 169.14% year-over-year to $163.1 million in Q1 2026; TTM through Mar 2026 was $738.4 million, a 12.49% decrease from a year earlier, with the FY2025 full-year figure at $635.9 million, down 56.6% from the prior year.
• Net Equity Issued and Repurchased slipped to $163.1 million in Q1 2026 per REGN's latest filing, from $503.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $682.1 million in Q1 2024 and bottomed at $31.5 million in Q2 2025.
• The 5-year median for Net Equity Issued and Repurchased is $301.0 million (2023), against an average of $290.0 million.
• Biggest YoY gain for Net Equity Issued and Repurchased was 453.91% in 2025; the steepest drop was 92.8% in 2025.
• Year by year, Net Equity Issued and Repurchased stood at $372.6 million in 2022, then fell by 19.22% to $301.0 million in 2023, then plunged by 69.8% to $90.9 million in 2024, then surged by 453.91% to $503.5 million in 2025, then plunged by 67.61% to $163.1 million in 2026.
• Per Business Quant, the three latest REGN Net Equity Issued and Repurchased figures stand at $163.1 million (Q1 2026), $503.5 million (Q4 2025), and $40.3 million (Q3 2025).